This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Leah J. Witt, MD: ...
Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...
Most patients with chronic obstructive pulmonary disease (COPD) remain untreated after diagnosis, leading to frequent exacerbations. After COPD diagnosis, prompt and effective single or dual ...
Why is it that we have not seen the urgency in COPD management we would expect for a disease of this burden and scale? As a trained pulmonologist, and having dedicated my career to advancing ...
The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...
This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...
WILMINGTON, DE — A new study conducted by the COPD Foundation and digital health company Phreesia highlights critical communication gaps between patients with chronic obstructive pulmonary disease ...
Compared with patients with only chronic obstructive pulmonary disease (COPD), patients with COPD and anxiety and/or depression had increased clinical and economic burden. Older patients with chronic ...
Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...
Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK. This is an ASCO Meeting Abstract ...
Do vitamin K antagonists affect COPD outcomes? New cohort data explore exacerbation and mortality risk compared with DOACs.